Opinion
Video
Overview of Phase 3 Perfluorohexyloctane Studies at AAO 2023
Richard Adler, MD, FACS, discusses corneal fluorescein staining data presented at AAO 2023 from the pooled analysis of 2 phase 3 studies.
EP: 1.Navigating Unmet Needs in Dry Eye Disease Therapies
EP: 2.Key Takeaways from Phase 4 Switch Trial Presented at AAO
EP: 3.Real World Benefit Related to Improving Corneal Staining
EP: 4.Overview of Phase 3 Perfluorohexyloctane Studies at AAO 2023
EP: 5.Updates from the SAHARA Trial at AAO 2023
EP: 6.Dual Mechanism Dry Eye Treatment Shows Promise for Symptoms and Compliance
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses phase 3 trial results for Miebo (perfluorohexyloctane ophthalmic solution), a drug being evaluated for treatment of evaporative dry eye disease in patients with meibomian gland dysfunction.
The phase 3 study compared Miebo (perfluorohexyloctane ophthalmic solution) to a vehicle for the ability to improve signs and symptoms of dry eye. Signs were assessed by corneal staining. After 4 weeks of treatment, Miebo (perfluorohexyloctane ophthalmic solution) demonstrated statistically significant improvements in both signs and symptoms compared with the vehicle, which were sustained through 8 weeks.
Adler notes Miebo produced rapid effects by targeting evaporation, a mechanism of action not previously explored for dry eye treatment. With a favorable safety profile and novel mechanism, Miebo offers an important new treatment option for dry eye disease.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
